相关临床试验
4
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
1
25.0%
Available
1
25.0%
招募中
2
50.0%
暂无批准数据
- Rznomics published research in Nucleic Acids Research demonstrating substantially enhanced circular RNA (circRNA) production using its proprietary Self-Targeting and Splicing (STS) technology. - The team optimized target-site selection and engineered the P1 construct, improving self-circularization efficiency by up to approximately seven-fold versus the original STS design. - For Factor VIII RNA of roughly 7.8 kilo-nucleotides, the optimized STS method achieved about two-fold higher circularization efficiency than the Permuted Intron–Exon (PIE) method. - The company anticipates the platform will support circRNA-based therapeutics and vaccines, with plans to expand into CAR-T therapies.
- Rznomics, a South Korean RNA gene therapy developer, has joined Lilly Gateway Labs in San Diego to accelerate its trans-splicing ribozyme platform and pipeline of more than 200 disease targets. - The move grants Rznomics access to wet-lab facilities and direct engagement with Lilly scientists and executives, supporting preclinical and clinical development. - Rznomics and Eli Lilly signed a research collaboration and licensing agreement in May 2025, reported at approximately ₩1.9 trillion ($1.4 billion), to co-develop a novel RNA editing therapy. - Rznomics plans to establish U.S. clinical infrastructure, expand global partnerships, and recruit top-tier R&D talent as part of its long-term strategy.
